Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTVNASDAQ:KPTINASDAQ:PRPHNASDAQ:RENB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$1.81-11.7%$3.01$1.78▼$17.31$44.10MN/A174,105 shs165,594 shsKPTIKaryopharm Therapeutics$4.85-1.4%$5.46$3.51▼$17.85$41.56M0.3382,759 shs71,800 shsPRPHProPhase Labs$0.37+8.2%$0.35$0.22▼$5.45$15.41M-0.472.68 million shs762,714 shsRENBRenovaro$0.33-1.6%$0.49$0.29▼$2.34$52.38M0.62965,733 shs1.75 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics-11.71%-12.77%-7.65%-54.86%+180,999,900.00%KPTIKaryopharm Therapeutics-1.42%-20.62%+15.20%-46.97%-70.34%PRPHProPhase Labs+8.24%+28.67%+22.06%+8.24%-92.74%RENBRenovaro-1.55%+5.36%-7.95%-55.53%-68.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTVArtiva Biotherapeutics1.9584 of 5 stars3.50.00.00.01.81.70.6KPTIKaryopharm Therapeutics3.7674 of 5 stars3.50.00.04.62.32.50.6PRPHProPhase Labs1.9178 of 5 stars0.05.00.00.02.61.71.3RENBRenovaro0.8664 of 5 stars0.02.00.00.01.93.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTVArtiva Biotherapeutics 3.00Buy$20.401,027.07% UpsideKPTIKaryopharm Therapeutics 3.00Buy$43.20790.72% UpsidePRPHProPhase Labs 0.00N/AN/AN/ARENBRenovaro 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PRPH, KPTI, RENB, and ARTV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025KPTIKaryopharm TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$34.00 ➝ $33.005/13/2025KPTIKaryopharm TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.005/13/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$54.00 ➝ $42.004/8/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.003/26/2025ARTVArtiva BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/25/2025ARTVArtiva BiotherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$23.00 ➝ $20.003/25/2025ARTVArtiva BiotherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$18.00 ➝ $18.003/25/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.003/3/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$75.00 ➝ $54.002/26/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $56.002/20/2025KPTIKaryopharm TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$45.00 ➝ $45.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTVArtiva Biotherapeutics$251K175.69N/AN/AN/A∞KPTIKaryopharm Therapeutics$145.24M0.29N/AN/A($1.47) per share-3.30PRPHProPhase Labs$6.77M2.28N/AN/A$2.74 per share0.13RENBRenovaroN/AN/AN/AN/A$0.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTVArtiva BiotherapeuticsN/AN/A0.00N/AN/AN/AN/AN/A6/23/2025 (Estimated)KPTIKaryopharm Therapeutics-$143.10M-$15.29N/AN/AN/A-52.62%N/A-39.58%N/APRPHProPhase Labs-$16.78M-$1.26N/AN/AN/A-217.64%-62.92%-30.22%5/20/2025 (Estimated)RENBRenovaro-$80.65M-$0.93N/A∞N/AN/A-61.84%-48.07%N/ALatest PRPH, KPTI, RENB, and ARTV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025PRPHProPhase Labs-$0.18N/AN/AN/A$2.45 millionN/A5/12/2025Q1 2025KPTIKaryopharm Therapeutics-$4.21-$2.77+$1.44-$2.77$35.12 million$30.02 million5/8/2025Q1 2025ARTVArtiva Biotherapeutics-$0.68-$0.83-$0.15-$0.83N/AN/A2/19/2025Q4 2024KPTIKaryopharm Therapeutics-$3.90-$3.60+$0.30-$0.24$30.29 million$30.54 million2/19/2025Q2 2025RENBRenovaroN/A-$0.02N/A-$0.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ARENBRenovaroN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTVArtiva BiotherapeuticsN/A11.3311.33KPTIKaryopharm TherapeuticsN/A1.702.93PRPHProPhase Labs0.481.471.33RENBRenovaroN/A0.060.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTVArtiva BiotherapeuticsN/AKPTIKaryopharm Therapeutics66.44%PRPHProPhase Labs9.45%RENBRenovaro71.41%Insider OwnershipCompanyInsider OwnershipARTVArtiva Biotherapeutics21.40%KPTIKaryopharm Therapeutics2.98%PRPHProPhase Labs20.70%RENBRenovaro21.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTVArtiva Biotherapeutics8124.36 millionN/AN/AKPTIKaryopharm Therapeutics3808.57 million122.72 millionOptionablePRPHProPhase Labs13041.88 million18.93 millionOptionableRENBRenovaro20158.72 million124.24 millionOptionablePRPH, KPTI, RENB, and ARTV HeadlinesRecent News About These CompaniesRenovaro Launches Augusta, an AI-Powered Precision Neurology PlatformMay 14 at 9:15 AM | globenewswire.comRenovaro gaat samenwerking aan met Amsterdam UMC voor kankerdiagnostiekMay 13 at 7:33 PM | nl.investing.comRenovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA DiagnosticsMay 13 at 9:15 AM | globenewswire.comRenovaro Inc. (NASDAQ:RENB) Shares Acquired by Geode Capital Management LLCMay 2, 2025 | marketbeat.comRENB-aandeel raakt 52-weeks dieptepunt van $ 0,32 door marktuitdagingenMay 1, 2025 | nl.investing.comRenovaro BioSciences expands collaboration with NebulApril 23, 2025 | markets.businessinsider.comRenovaro Inc. Expands Collaboration with Nebul to Enhance Early Cancer Detection Through Advanced AI TechnologyApril 22, 2025 | quiverquant.comRenovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic ProgramsApril 22, 2025 | globenewswire.comRenovaro riskeert Nasdaq-notering te verliezen door te lage aandelenkoersApril 18, 2025 | nl.investing.comRenovaro BioSciences, BioSymetrics close merger transactionApril 9, 2025 | markets.businessinsider.comRenovaro Inc: Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision MedicineApril 9, 2025 | finanznachrichten.deRenovaro fuseert met BioSymetrics voor AI-gedreven medicijnontwikkelingApril 9, 2025 | nl.investing.comRenovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision MedicineApril 9, 2025 | globenewswire.comPredictive Oncology Ends Merger Talks with RenovaroApril 7, 2025 | tipranks.comRenovaro Biosciences stuit op tegenslag bij fusie met Predictive OncologyApril 6, 2025 | nl.investing.comRenovaro Inc: Renovaro Provides Update to Definitive Agreement with Predictive OncologyApril 4, 2025 | finanznachrichten.deRenovaro BioSciences provides update to agreement with Predictive OncologyApril 4, 2025 | markets.businessinsider.comRenovaro Shares Fall After Merger SetbackApril 4, 2025 | marketwatch.comRenovaro says Predictive Oncology terminates merger transactionApril 4, 2025 | markets.businessinsider.comRenovaro Provides Update to Definitive Agreement with Predictive OncologyApril 4, 2025 | globenewswire.comRenovaro Biosciences Advances Financing for AI-Driven Integration and Strategic Expansion in Oncology through Acquisition of Predictive OncologyMarch 5, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRPH, KPTI, RENB, and ARTV Company DescriptionsArtiva Biotherapeutics NASDAQ:ARTV$1.81 -0.24 (-11.71%) As of 05/14/2025 04:00 PM EasternArtiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Karyopharm Therapeutics NASDAQ:KPTI$4.85 -0.07 (-1.42%) As of 05/14/2025 04:00 PM EasternKaryopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.ProPhase Labs NASDAQ:PRPH$0.37 +0.03 (+8.24%) As of 05/14/2025 04:00 PM EasternProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Renovaro NASDAQ:RENB$0.33 -0.01 (-1.55%) As of 05/14/2025 04:00 PM EasternRenovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
